ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2025
Peripheral blood inflammatory markers as predictive and prognostic indicators in neoadjuvant immunotherapy for non-small cell lung cancer.
Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectivesNeoadjuvant immunotherapy has demonstrated favorable efficacy in patients with resectable non-small cell lung cancer (NSCLC). However, its clinical application remains limited by the lack of reliable and non-invasive biomarkers. Although existing histological biomarkers such as programmed death-ligand 1 (PD-L1) and tumor mutation burden (TMB) can be used for reference, they rely on invasive sampling and are susceptible to tumor heterogeneity. This study evaluated a series of peripheral blood inflammation-related indicators, including neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and interleukin-6 (IL-6), to explore their potential as non-invasive predictive and prognostic biomarkers for NSCLC. Furthermore, a prediction model based on the above indicators was constructed to provide a practical and feasible tool for optimizing individualized clinical management in patients with resectable NSCLC.
methodsA retrospective analysis was conducted on 144 patients with resectable (stage IB-IIIB) NSCLC who underwent surgery after receiving neoadjuvant immunotherapy combined with chemotherapy at the Second Xiangya Hospital, Central South University, between 2019 and 2022. Peripheral blood-related indicators at baseline and before surgery were collected. Clinical data that might influence treatment efficacy were also recorded, including age, sex, body mass index, smoking history, pathological type, clinical stage, and use of immune checkpoint inhibitors. The relationships between peripheral blood inflammatory indicators (NLR, LMR, PLR, SII, and IL-6) and objective response rate (ORR), pathological complete response (pCR), major pathological response (MPR), and disease-free survival (DFS) were analyzed. Receiver operating characteristic (ROC) curves were used to determine optimal cutoff values for each indicator. A prediction model for the efficacy of neoadjuvant immunotherapy in NSCLC was constructed using least absolute shrinkage and selection operator (LASSO) regression combined with a multivariate Cox proportional hazards model.
resultsThe median age of included patients was 58 years, and 91.0% (131/144) were male. Among pathological types, squamous cell carcinoma accounted for 74.3% (107/144), adenocarcinoma for 22.9% (33/144), and other types for 4 cases. The overall ORR, pCR, and MPR rates were 69.2%, 42.4%, and 61.5%, respectively. Univariate analysis showed that patients with squamous cell carcinoma had significantly higher ORR (
conclusionsNeoadjuvant immunotherapy demonstrates favorable clinical efficacy in patients with NSCLC, particularly in those with squamous cell carcinoma. Meanwhile, peripheral blood inflammation-related indicators may serve as important biomarkers for predicting the efficacy and prognosis of neoadjuvant immunotherapy in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.